Cytochroma Inc.

02.06.2005 – 14:07
Cytochroma Reports Successful Efficacy Trial for Novel Topical Treatment of Psoriasis
Markham, Canada (ots/PRNewswire) - Cytochroma Inc. today announced results from a Phase Ia clinical study for CTA018, a novel vitamin D analog developed for the treatment of psoriasis. The study, involving 17 healthy subjects with mild to moderate plaque psoriasis, was designed to characterize the local efficacy and safety of three concentrations of CTA018. Results ...
mehr
05.05.2005 – 14:06
Cytochroma Secures Additional Financing
Markham, Canada (ots/PRNewswire) - Cytochroma Inc. announced today that the Company has received the first tranche of a CDN $15 million financing. The funds will be used by Cytochroma to continue advancement of CTA018 towards a Phase II clinical trial for psoriasis as well as to extend its pipeline of late-stage preclinical products. This recent round of financing was led by VenGrowth Private Equity Partners Inc. ...
mehr